In ER+ breast cancers, PI3K/PTEN/Akt/mTORC1 pathway activation results in both estrogen-dependent and estrogen-independent ER activity and loss of therapy response to hormonal therapies [24]. This evidence concerns the gene ESR1 and breast cancer.